This trial is active, not recruiting.

Conditions coronary artery disease, electrophysiology, cardiovascular disease
Sponsor Intermountain Health Care, Inc.
Start date October 1994
End date January 2024
Trial size 30000 participants
Trial identifier NCT00406185, 128-db1


The purpose of the registry is to collect and analyze clinical and laboratory data and tissue samples from patients who are diagnosed with any type of heart disease and to collect the same information and samples from healthy controls in participating Intermountain Healthcare facilities.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective

Primary Outcomes

Outcome Risk
time frame: 30 years

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: 1. The patient (male or non-pregnant female) must be > 18 years of age. 2. The patient or legally authorized representative must sign a written informed consent, prior to the procedure, using a form that is approved by the local Institutional Review Board. Exclusion Criteria: 1. Neither patient nor patient representative understands spoken English. 2. Neither patient nor the patient's personal representative is willing to give written consent for participation. 3. Healthy control patients must sign their own consent document.

Additional Information

Official title Database Registry of the Intermountain Heart Collaborative Study
Principal investigator Joseph B Muhlestein, MD
Description This is a registry (database) project; there are no investigational treatments, drug or procedures associated with participation in registry activities. This project is an organized data gathering and storing (database) endeavor with specific focus on the precursors, modifiers, biological, and genetic parameters of heart disease and related medical conditions. Data collection will not immediately influence the course of treatment for any patient.Sample testing and data utilization for basic science, clinical, and epidemiologic and publication projects can be initiated using the databank. The registry will enable researchers to determine best medical practices for predicting, preventing, and treating heart disease. The registry will: 1) develop standard methods to collect data and specimens which will be used for research to characterize patients diagnosed with heart disease as well as healthy controls and to assess differences in demographics and patient outcomes in both populations; 2) collect, process, and store patients' clinical data and tissue/blood samples; 3) analyze data collected; 4) use these resources to identify genes, genetic polymorphisms, genetic mutations, clinical methods and procedures, and/or biomarkers that predict, prevent, or treat heart disease and/or are associated correlate with lifestyle or disease outcomes; 5) publish and disseminate results.
Trial information was received from ClinicalTrials.gov and was last updated in September 2015.
Information provided to ClinicalTrials.gov by Intermountain Health Care, Inc..